BioPharmSignal logoBioPharmSignal

Biotech News

PepGen Announces Issuance of U.S. Patent for Proprietary PGN-EDODM1 Molecule

PepGen (PEPG)PepGenCompany update

Composition of matter patent covers the Company’s novel PGN-EDODM1 molecule and serves as a cornerstone of its expanding patent portfolio BOSTON --(BUSINESS WIRE)--Nov. 12, 2025-- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide

Related news

PEPGPepGen2026-08-06 11:30 EST

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

PEPGPepGen2026-05-21 11:00 EST

PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program

View all latest news

PepGen

Oligonucleotide Delivery Company PepGen develops Enhanced Delivery Oligonucleotides intended to transport therapeutic oligonucleotides into skeletal muscle. PGN-EDODM1 PGN-EDODM1 is designed to correct RNA splicing in myotonic dystrophy type 1 by releasing pathogenic RNA and restoring downstream protein expression. FREEDOM2 The FREEDOM2...

Recent company news

PEPGPepGen2026-08-06 11:32 EST

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

PEPGPepGen2026-08-06 11:30 EST

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

PEPGPepGen2026-05-21 11:00 EST

PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program

PEPGPepGen2026-05-12 20:05 EST

PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

PEPGPepGen2026-03-30 20:05 EST

PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data

Stock data

Close
3.14 USD
Market cap
100.3M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States